Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery time 29% Improvement Relative Risk Viral clearance -183% c19hcq.org Niwas et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 29 patients in India Faster recovery with HCQ (p=0.0082) Niwas et al., Advances in Respiratory Medicine, doi:10.5603/ARM.a2020.0139 Favors HCQ Favors control
Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience
Niwas et al., Advances in Respiratory Medicine, doi:10.5603/ARM.a2020.0139
Niwas et al., Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience, Advances in Respiratory Medicine, doi:10.5603/ARM.a2020.0139
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 12 hospitalized patients in India treated with CQ and 17 controls, showing faster recovery with treatment. There was no significant difference in viral clearance. The CQ group mean age was 41.3 vs. 47.6 for controls. This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
recovery time, 29.2% lower, relative time 0.71, p = 0.008, treatment mean 6.3 (±2.7) n=12, control mean 8.9 (±2.2) n=17.
risk of no viral clearance, 183.3% higher, RR 2.83, p = 0.55, treatment 2 of 12 (16.7%), control 1 of 17 (5.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Niwas et al., 1 Nov 2020, retrospective, India, peer-reviewed, mean age 45.5, 17 authors.
Contact: rniwasaiims@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: ORIGINAL RESEARCHES Ram Niwas 1, Aneesa Shahul S 1, M K Garg 2, Vijaya Lakshmi Nag 3, Pradeep Kumar Bhatia 4, Naveen Dutt 1, Nishant Chauhan 1, Jaykaran Charan 5, Shahir Asfahan 1, Praveen Sharma 6, Pankaj Bhardwaj 7, Mithu Banerjee 6, Pawan Garg 8, Binit Sureka 8, Gopal Krishna Bohra 2, Maya Gopalakrishnan 2, Sanjeev Misra 9 1 Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India Department of General Medicine, All India Institute of Medical Sciences Jodhpur, India 3 Department of Microbiology, All India Institute of Medical Sciences Jodhpur, India 4 Department of Anaesthesiology & Critical Care, All India Institute of Medical Sciences Jodhpur, India 5 Department of Pharmacology, All India Institute of Medical Sciences Jodhpur, India 6 Department of Biochemistry, All India Institute of Medical Sciences Jodhpur, India 7 Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences Jodhpur, India 8 Department of Diagnostic & Interventional Radiology, All India Institute of Medical Sciences Jodhpur, India 9 Department of Surgical Oncology, All India Institute of Medical Sciences Jodhpur, India 2 Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience Abstract Introduction: Chloroquine and its analogues are currently being investigated for the treatment and post exposure prophylaxis of COVID-19 due to its antiviral activity and immunomodulatory activity. Material and methods: Confirmed symptomatic cases of COVID-19 were included in the study. Patients were supposed to receive chloroquine (CQ) 500 mg twice daily for 7 days. Due to a change in institutional protocol, initial patients received chloroquine and subsequent patients who did not receive chloroquine served as negative controls. Clinical effectiveness was determined in terms of timing of symptom resolution and conversion rate of reverse transcriptase polymerase chain reaction (RT-PCR) on day 14 and day 15 of admission. Results: Twelve COVID-19 patients formed the treatment arm and 17 patients were included in the control arm. The duration of symptoms among the CQ treated group (6.3 ± 2.7 days) was significantly (p-value = 0.009) lower than that of the control group (8.9 ± 2.2 days). There was no significant difference in the rate of RT-PCR negativity in both groups. 2 patients out of 12 developed diarrhea in the CQ therapy arm. Conclusion: The duration of symptoms among the treated group (with chloroquine) was significantly lower than that of the control group. RT-PCR conversion was not significantly different between the 2 groups. Key words: COVID-19, chloroquine, viral conversion, safety profile Adv Respir Med. 2020; 88: 515–519
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit